Navigation Links
CMX001 Shows Antiviral Activity in Immunocompromised Transplant Patients With Severe Adenovirus Infection
Date:5/11/2011

DURHAM, N.C., May 11, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing oral antiviral therapeutics, today presented data showing that the majority of immunocompromised patients with severe adenovirus infections who were treated with Chimerix’s lead antiviral compound, CMX001, had a > 99% decrease in viral load compared to baseline after two weeks of therapy.  These CMX001 clinical data, described in an oral presentation today at the 24th Annual International Conference on Antiviral Research (ICAR) held in Sofia, Bulgaria, demonstrate the unique activity of CMX001 against adenovirus (AdV), a life-threatening viral infection without an approved treatment.  

“In the most challenging and urgent of Emergency IND cases, CMX001 has demonstrated antiviral activity against a full spectrum of double-stranded DNA infections including AdV,” said Wendy Painter, MD, Chief Medical Officer for Chimerix. “The results presented in this oral session today further support our efforts to advance CMX001 as a much-needed therapeutic for critically ill transplant patients, including pediatric post-stem cell transplantation patients with life-threatening adenovirus infections.  We also believe that this data will contribute to broader development of CMX001 against the breadth of double-stranded DNA viruses.”  

Chimerix’s CMX001 is in development as a potential broad-spectrum antiviral agent with promising activity against all classes of double-stranded DNA (dsDNA) viruses that can infect humans.  CMX001 is currently in clinical studies against multiple infections including cytomegalovirus and advenovirus, and has the potential to meet a significant unmet medical need for patients at risk of these dsDNA life-threatening viral infections.

The oral presentation provided an analysis of twenty-two patients with adenovirus viremia who had received at least two doses of CMX001, had measu
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerixs Lead Antiviral CMX001
2. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
3. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
4. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
5. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
6. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
7. New Device to Support Blood Circulation for Heart Patients Shows Improved Outcomes Compared to Current Treatment
8. Study Shows Same Day PET-Guided Biopsy May Expedite Pre-Operative Work-up For Breast Cancer Patients and Reduce Radiation Exposure
9. Chronic Disease Research Group Study Shows Daily Home Hemodialysis Therapy with the NxStage® System One™ is Associated with Lower Risk of Mortality and Higher Survival Estimates Compared to Conventional Thrice-Weekly Dialysis
10. Tissue Engineering Shows Promise to Revolutionize Transplant Medicine
11. Phase I Research of Extended-Release Topiramate Shows Less Fluctuation in Plasma Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Ga. , Oct. 31, 2014  Digirad Corporation ... to PDI, Inc. (Nasdaq: PDII ), a ... of Digirad,s proposal to acquire the company.  ... meaningful discussions regarding a transaction and to operate in ... its cash, or take on additional debt, on acquisitions ...
(Date:10/31/2014)... 31, 2014 Mast Therapeutics, Inc. (NYSE MKT: ... for the quarter ended September 30, 2014. ... said:  "The third quarter was productive for Mast. Consistent with ... MST-188 for sickle cell disease is on track to ... have opened 50 study sites in the U.S. and ...
(Date:10/31/2014)... , October 31, 2014 ... Corporation (NASDAQ: CELG ), Bristol-Myers Squibb Co. ... UNH ), Sanofi SA (NYSE: ... members receive these notes ahead of publication. To reserve ... . , ,-- ,Celgene Corporation Research Reports ,On October ...
Breaking Medicine Technology:Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6
... Champions Biotechnology, Inc. (OTC Bulletin Board: ... aimed at accelerating the development and enhancing the value ... Schonau, Champions, Chief Financial Officer. Mr. Schonau indicated that ... to pursue other opportunities. Champions is seeking chief financial ...
... Zimmer Holdings, Inc. (NYSE and SIX: ZMH) announced today ... be broadcast live over the Internet on Thursday, January 27, ... the quarterly results will be made available at 7:00 a.m. ... The live audio webcast can be accessed via Zimmer,s ...
Cached Medicine Technology:Champions' CFO Resigns 2Zimmer Holdings Announces Live Audio Webcast and Conference Call of Fourth Quarter and Year End 2010 Results 2
(Date:10/31/2014)... October 31, 2014 At the start ... families narrowly escaping carbon monoxide poisoning in their homes. ... weeks away, one family-owned, Missouri-based heating and cooling company ... making sure families start the home heating season with ... secure. , Beginning Nov. 1, 2014, E and ...
(Date:10/31/2014)... -- Surgery for low back pain caused by spinal ... you live, a new report says. "Nearly 80 ... some point in their lives, and about 30 million ... spine problem," co-author Brook Martin, of the Dartmouth Institute ... college news release. In spinal stenosis, thickening of ...
(Date:10/31/2014)... DARIEN, IL – New research suggests that insomnia is ... crashes and other unintentional fatal injuries. The results underscore ... of the National Healthy Sleep Awareness Project. , Results ... in a dose-dependent manner with the number of insomnia ... were 2.8 times more likely to die from a ...
(Date:10/31/2014)... October 31, 2014 The Suspension Revolution ... workout program was developed by Dan Long, a suspension ... as a fitness professional and life coach. The author ... having toned muscles is not impossible , The Suspension ... suspension training. Suspension training promises efficiency when it comes ...
(Date:10/31/2014)... 31, 2014 Florida Air Academy, ... girls in grades 6-12, is taking the lead ... injuries and concussions, becoming the first high school ... (Immediate Post-Concussion Assessment and Cognitive Testing) computerized assessment ... Player' lawsuit grabs the headlines, and the Centers ...
Breaking Medicine News(10 mins):Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:Florida Air Academy Tackling Concussions Head-On 2Health News:Florida Air Academy Tackling Concussions Head-On 3
... byproduct even showed protection for women, study finds, , , ... byproduct that some research has linked to certain cancers, ... and may even offer slight protection for women, new ... than 120,000 men and women, Dutch researchers reported that ...
... of the American Academy of Disaster Medicine,s (AADM), Gary ... from a disaster medicine perspective on the recent swine ... why improvements are needed to the U.S. public health ... or pathogen; how disaster medicine specialists are helping other ...
... In conjunction with DURECT Corporation,s (Nasdaq: DRRX ... invited to listen to the conference call that will be ... at 4:30 pm Eastern Time (1:30 pm Pacific Time).A live ... DURECT,s homepage at http://www.durect.com ...
... In the wake of media reports on the outbreak ... services company, is offering advice to travelers who may already ... take.Over one million American businesspeople, expatriates, students studying abroad and ... offers five basic tips:, , ...
... Offers Significant Improvement - , , CHICAGO ... at the American Urological Association,s (AUA) Annual Conference show ... and sustained improvements of both irritative and obstructive urinary ... within three to four days of starting treatment. ...
... deaths are likely , , TUESDAY, April 28 (HealthDay News) -- ... United States continued to climb Tuesday, to 64, with all ... York City high school that had previously reported 18 cases ... are 64 confirmed cases in the United States in five ...
Cached Medicine News:Health News:Acrylamide Doesn't Raise Lung Cancer Risk 2Health News:Acrylamide Doesn't Raise Lung Cancer Risk 3Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 2Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 3Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 4Health News:Combating Swine Flu: HTH Worldwide Offers Tips to Travelers 2Health News:Combating Swine Flu: HTH Worldwide Offers Tips to Travelers 3Health News:Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients 2Health News:Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients 3Health News:Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients 4Health News:Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients 5Health News: U.S. Swine Flu Cases Surpass 60 2Health News: U.S. Swine Flu Cases Surpass 60 3
... experience, the SSD-1000 is a high performance ... our advanced technologies and over 5 decades ... technology as our more expensive systems, the ... compact and mobile setting., We also employ ...
... CONMED's family of products allows you to ... generators feature proprietary Energy Synchronous Processing Technology. ... current and voltage in all operational modes. ... to sample current and voltage over 450,000 ...
The DuraSeal System includes an innovative polyethylene glycol hydrogel sealant and applicator packaged in a single-use kit which can be stored at room temperature for convenience and quick preparati...
... and Tissue Adhesive is a formulation of ... mussel). These proteins are the key components ... to anchor itself to solid substrates in ... Tissue Adhesive is used to attach cells ...
Medicine Products: